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This manuscript is dedicated to the memory of Laura SweetAbstract As BRCA1 expression is often suppressed in sporadic
ovarian carcinoma we characterized the regulation of the 231nt
proximal ‘L6’ fragment of the BRCA1 promoter in two human
ovarian surface epithelial cell and two sporadic ovarian carci-
noma cell lines. Two individual regulatory elements within L6,
the ‘RIBS’ element and the potential ‘CRE’ element were each
necessary, but alone not suﬃcient for L6 activation in all four
cell lines. The latter element showed some aﬃnity for the CREB
transcription factor, but cAMP pathway stimulation failed to
promote its activation. This element did, however, interact with,
and was activated by, c-Jun and Fra2 which suggests that it can
interact with AP1-like transcription factors and that it may act
co-operatively with RIBS-binding factors to regulate BRCA1
transcription in ovarian cells.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Tumor suppressor1. Introduction
Germline mutations in the BRCA1 gene contribute to hered-
itary breast and epithelial ovarian carcinoma formation [1].
However, these cancers most often arise sporadically, a condi-
tion in which somatic BRCA1 mutations are extremely rare [1–
6]. Despite this, BRCA1 protein levels are often reduced in
sporadic tumors and the severity of this reduction has been
positively correlated with increased grade in both the breast
[7,8] and the ovary [9–16]. Thus, non-mutational suppression
of BRCA1 expression is likely an important event in sporadic
tumorigenesis. Altered regulation of the BRCA1 promoter
likely helps to mediate this suppression given that mRNA lev-
els are often reduced and that the promoter is methylated in a
signiﬁcant proportion of spontaneous tumors [12–17].*Corresponding author. Fax: +1 604 822 2316.
E-mail address: roskelly@interchange.ubc.ca (C.D. Roskelley).
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doi:10.1016/j.febslet.2007.03.072The BRCA1 promoter lies within a 218 bp intragenic region
between the bi-directionally controlled BRCA1 and NBR2
genes and its regulation has been examined in considerable de-
tail in breast carcinoma cells [18–26]. Deletion analysis of this
region identiﬁed a 56 bp sequence from nucleotide 204 to
148 relative to the major BRCA1 transcriptional start site
that maximally activates the promoter [19] and contains the
independently described ‘positive regulatory region’ (PRR)
from nucleotide 202 to 166 [20,26]. There are two sub-re-
gions within the PRR that act as strong positive regulatory ele-
ments of the promoter [27]. The ﬁrst is the ‘RIBS’ element
(204 nt to 182 nt), which binds to, and is activated by,
the ETS transcription factor complex GABPa/b in MCF-7
breast cancer cells [21]. The second is a putative CRE element
located just downstream of the RIBS element (174 nt to
167 nt; [22]) which is of particular interest because in vitro
methylation of a CpG nucleotide in this site decreases pro-
moter activity [28] and it lies within a region that is frequently
hypermethylated in sporadic ovarian tumors [13,14].
To date, the transcriptional regulation of the BRCA1 pro-
moter has not been thoroughly characterized in ovarian cells
[29]. Therefore, in this report we examined its regulation in
sporadic tumor-derived ovarian carcinoma cells and in ovarian
surface epithelial (OSE) cells, which are a major target for
oncogenic transformation in the ovary [30]. We found that
the RIBS and CRE subregions were strong positive regulatory
elements in all the ovarian cell lines examined. Importantly,
each element was necessary, but not independently suﬃcient
for optimal promoter activation. We also found that the puta-
tive CRE element did not appear to be acting as a classical
cAMP-response element in ovarian cells, as it was also capable
of binding, and was activated by, the AP-1 transcription factor
family members, c-Jun and Fra2. Thus, misregulation of sig-
naling pathways that inﬂuence AP-1 transcription factor activ-
ity may modulate BRCA1 expression during sporadic ovarian
carcinoma formation.2. Materials and methods
2.1. Cell lines and cell culture
The extended lifespan IOSE-29 and IOSE-80 lines were generated as
previously described [31]. A population of the IOSE-80 cells thatation of European Biochemical Societies.
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80pc cell line. The OVCAR-3 and SKOV-3 carcinoma lines were ob-
tained from the American Type Culture Collection (ATCC). All cell
lines were grown in a 199:105 medium (Sigma, St. Louis MO) with
5% fetal bovine serum and gentamycin (50 lg/ml).2.2. RNA isolation and RT-PCR
Total RNA was extracted with Trizol (Invitrogen, Carlsbad CA)
and cDNA was synthesized using the thermoscript RT-PCR system
(Invitrogen). The primer sequences used for BRCA1 transcript ampli-
ﬁcation were 5 0-ATGCTGAATGAGCATGATTTG-3 0 (Forward); 5 0-
AGAGTGCTACACTGTCCAAC-3 0 (Reverse) which generate a
352 bp fragment [16]. Control primers for b-actin were used which gen-
erates a 510 bp fragment [32]. Both sets of primers span intron bound-
aries to ensure mRNA-speciﬁc ampliﬁcation.2.3. BRCA1 promoter reporter and transactivation assays
The BRCA1 promoter, the 5 0 deletion mutants, and the site-directed
point mutants were generated by PCR [21] and cloned into the pRL
reporter vector (Promega, Madison WI). For the reporter assays,
1 · 105 cells were transiently co-transfected using DMRIE-C (Invitro-
gen) with 0.5 lg of the indicated reporter construct, 0.25 lg (total) of
the indicated expression vector construct(s) (i.e., for the AP-1 transac-
tivation assays), and 10 ng of a control CMV-driven reporter construct
for normalization of transfection eﬃciency. Forty-eight hours post-
transfection, the cells were lysed and assayed using the dual luciferase
kit (Promega). cDNAS for c-Jun and Fra2 cloned into the pcDNA3
expression vector were generously provided by Irina Udalova
(Oxford University, Oxford, UK; [33]). For activation of the cAMP
pathway cells were treated with 20 lM Forskolin (Sigma) or DMSO
in the presence of 0.5% FBS for 24 h prior to assaying for luciferase
activity.2.4. Multimerized element reporter constructs
The putative CRE containing BRCREO element was repeated ﬁve
times and subsequently cloned into a reporter construct to generate
the ‘BRCREO Multimer’. The BRCREO Mutant multimer contains
the same two point mutants that were generated for the BRCREO mu-
tant probe utilized for the bandshift assays. The pCRE-Luc, (Strata-
gene, La Jolla CA) which contains four tandem consensus CRE
elements linked to the ﬁreﬂy luciferase gene, was used as the bona ﬁde,
cAMP responsive ‘Control CRE-Multimer,’ that is forskolin respon-
sive [22]. Both the AP-1 WT and the AP-1 Mutant multimer constructs
were generously provided by Dr. L.R. Bernstein (Texas A&M Univer-
sity, College Station, TX; [34]). The multimerized AP-1 Mutant ele-
ment contains two point mutations that abolish the AP-1 recognition
sequence [35].
2.5. Forskolin stimulation and Western blotting
Sub-conﬂuent cells were rinsed, serum-starved for three hours and
stimulated with 20 lM forskolin or vehicle control (DMSO) for an
additional 2 h. Cells were then rinsed brieﬂy in PBS and lysed in RIPA
lysis buﬀer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Np-40, 0.5% so-
dium deoxycholate, 0.1% SDS) containing protease and phosphatase
inhibitors. Protein lysates were analyzed by standard Western blotting
procedures and membranes were probed for antibodies against either
phosphorylated CREB at serine 133 (antiserum # 5322) [36] or actin
(Sigma) as a loading control.
2.6. Nuclear extracts and gel mobility shift assays
Nuclear extracts, BRCA1 promoter-speciﬁc probes, and bandshifts
were all prepared and/or carried out as described previously [21]. Com-
petition bandshift assays were carried out by the addition of 1, 5 or
50 ng of unlabelled competitor oligonucleotides to standard bandshift
reactions containing 1 ng of the labeled CRE consensus sequence
oligonucleotide derived from the somatostatin promoter. Nuclear
extracts were added last. The sequence of the somatostatin-CRE probe
is (50-AGAGATTGCCTGACGTCAGAGAGCTAG-30). The sequence
of the BRCREO probe is: 5 0-CTTTCCTTTTACGTCATCCGGG-
GGCAGACT-3 0 3 0-GGAAAATGCAGTAGGCCCCCGTCTGA-5 0
while the sequence of the BRCREO mutant probe is 5 0-CTTT-
CCTTTTAATTCATCCGGGGGCAGACT-3 0 3 0-GGAAAATTA-
AGTAGGCCCCCGTCTGA-5 0 with the mutated sites underlined[22]. Antibodies for CREB (Cat#240), Fra2 (#Q20), Fos (#D-1) and
c-Jun (#H-79) were all obtained from Santa Cruz Biotech (Santa Cruz,
CA).3. Results
3.1. BRCA1 expression and promoter activity in ovarian cells
To ensure that the cell lines chosen for this study all express
endogenous BRCA1 we ﬁrst carried out semi-quantitative RT-
PCR. Under proliferative conditions, the BRCA1-speciﬁc
transcript (Fig. 1A), and the 220 kD protein product (data
not shown) was present in all four cell lines.
In previous studies of BRCA1 promoter regulation in breast
cells, we determined that a 231 bp fragment (204nt to +27nt;
the ‘L6’ promoter) has optimal transcriptional activity [21,22].
Similarly, we found that the L6 promoter exhibited strong
activity in all four of the ovarian cell lines tested, even when
compared to a much larger ‘FL’ fragment that spanned
997 bp of the promoter (Fig. 1B).
3.2. The ‘RIBS’ and ‘CRE’ elements positively regulate the
BRCA1 promoter
A 5 0 deletion analysis of the L6 promoter indicated that the
loss of the ﬁrst 22 bp region caused a decrease in activity
(L6dR mutant) so severe that further deletions had no addi-
tional eﬀect (Fig. 1B). Thus the 22 bp ‘RIBS’ element that is
deleted in the L6dR fragment is required for BRCA1 promoter
activation.
There are three putative ETS binding sites in the 5 0 end of
the L6 promoter fragment. Two of these sites lie within the
RIBS element itself while the third site is immediately down-
stream. To assess their functional importance in ovarian cells
we created point mutants in all three sites (Fig. 2A) and com-
pared the activity of this L6-ATC mutant to wild-type L6
(Fig. 2B). These point mutations reduced the promoter activ-
ity, but the decrease was much less pronounced than in the
L6dR mutant (Fig. 1B). Thus, while the ETS sites are function-
ally important in ovarian cells there may be other, as yet
unidentiﬁed, positive elements in the 5 0 end of the promoter
that contribute to its maximal RIBS-dependent activation.
We next analyzed the importance of a putative CRE binding
region located immediately downstream of the RIBS element
by generating two point mutations within the CRE site to cre-
ate the L6CRE-M mutant (Fig. 2A). Unlike the L6-ATC mu-
tant, the L6CRE-M mutant completely abrogated L6
promoter activity in all four ovarian lines (Fig. 2B). Thus,
the CRE element is a second positive regulatory element that
is required for BRCA1 promoter activation. Furthermore,
the observations that the 5 0 RIBS deletion which still contains
an intact CRE element (Fig. 1B) and the L6CRE-M mutation
which still contains an intact RIBS element (Fig. 2B) both
completely abolish L6 activity indicate that while each is nec-
essary, neither element alone is suﬃcient to activate the other-
wise intact BRCA1 promoter.
3.3. Characterizing the CRE element in ovarian cells
Given that a precise mutation within the putative CRE ele-
ment completely abrogated the activity of the BRCA1 pro-
moter, we decided to more fully characterize its regulation in
ovarian cells. We ﬁrst carried out bandshift assays using the
‘BRCREO’ probe that contains and ﬂanks the CRE element
AB
Fig. 1. BRCA1 expression and promoter analysis in ovarian cells (A) RT-PCR was performed to detect the presence of a 352 bp fragment of the
BRCA1 transcript. The MCF-7 breast cell line was used as a positive control, and negative water controls from the reverse transcriptase reaction
[dH2O(1)] and the PCR reaction [dH2O(2)] were also included. Ampliﬁcation of a 510 bp fragment of the beta-actin transcript was used to
demonstrate cDNA equivalency. (B) The transcriptional activity of a series of 5 0 deletion mutants of the BRCA1 proximal promoter was assessed.
Nucleotide numbers of mutant endpoints are shown in relation to the BRCA1 transcriptional start site (not to scale). Highlighted in the schematic are
the previously characterized RIBS element, three putative ETS-binding sites (light grey boxes) and the CRE element (dark grey box). The open boxes
represent other potential regulatory regions that have not yet been characterized in ovarian cells. The average relative transcriptional activity of each
mutant is expressed as a percentage of the maximal L6 fragment (±S.D., n = 3; one representative experiment of three).
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CAR-3 formed a DNA/protein complex with this probe
(Fig. 3B; ‘–’ lane). We found that the addition of a CREB-spe-
ciﬁc antibody caused only a modest supershifted complex.
Thus, to further characterize the BRCREO as a putative
CRE site, we performed competition bandshift assays using
a labeled genuine CRE containing probe (from the somotasta-
tin promoter) and utilized either the wild-type or mutant
BRCREO probes as cold competitors. In nuclear extracts from
both IOSE-80pc and the OVCAR-3, the wild-type BRCREO
was able to compete for binding, but only partially and/or in
the presence of high levels of competing oligonucleotide, while
the BRCREO mutant had minimal eﬀect indicating the speci-
ﬁcity of the DNA/protein interactions to this site (Fig. 3C and
D). This suggests that although the BRCREO element shows
some commonality between a genuine CRE containing se-quence and weak CREB binding potential, it may not be solely
acting as a classical cAMP-responsive element in ovarian cells,
and may be regulated by additional transcription factors.
To further address this possibility we used a reporter con-
struct containing ﬁve tandem copies of the BRCREO element
placed upstream of a minimal promoter and then analyzed its
activity after treatment with the cAMP pathway stimulator for-
skolin. As a positive control we analyzed the forskolin-respon-
siveness of a multimerized, bonaﬁde CRE element (CRE
multimer). In both IOSE-80pc and OVCAR-3 cells, forskolin
treatment caused an increase in overall CREB phosphorylation
at serine-133 (Fig. 4A). Despite this, forskolin treatment failed
to stimulate the BRCREOmultimer or a minimal negative con-
trol promoter in IOSE-80pc cells, but it did substantially
increase the activity of the positive control CRE multimer
(Fig. 4B). In OVCAR-3 cells, forskolin treatment actually
AB
Fig. 2. Point mutational analyses of the ETS binding sites and the putative CRE element. (A) A schematic of the L6 promoter illustrating the
location and nature of the point mutations introduced into each of the three ETS binding sites, and the putative CRE element. (B) Transcriptional
activities of the L6-ATC triple mutant and the L6CRE-M mutant were determined. The data are expressed as the percentage activity relative to the
maximal L6 promoter construct (mean ± S.D., n = 3; one representative experiment of three).
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imal promoter while it did increase the activity of the bonaﬁde
CRE multimer, albeit to a lesser degree than in IOSE cells
(Fig. 4C). Thus, stimulation of the cAMP signaling pathway
alone did not activate the putative CRE element within the
BRCA1 promoter in ovarian cells.
3.4. The CRE element acts as a modiﬁed AP-1-binding site in
ovarian cells
Comparative sequence analysis suggested that the putative
CRE site might also be an AP-1 binding site. Therefore, we
performed bandshift assays on BRCREO probe/nuclear ex-
tract complexes using antibodies against AP-1 transcription
factor components (Fig. 5A). Interestingly, a clear, strong
supershift was observed with an antibody directed against c-
Jun. While antibodies directed against the c-Jun binding part-
ner c-Fos failed to generate a discernible supershift, the addi-
tion of an antibody directed against the alternative binding
partner, Fra2, did.
To assess the functional relevance of the c-Jun and the Fra2
binding to the BRCA1 CRE element, we carried out co-trans-
fections with reporter and expression vector constructs. Both
IOSE-80pc and OVCAR-3 cells were responsive to a combina-
tion of c-Jun and Fra2, as expression of the two factors to-
gether, but not singly, stimulated the activity of a positive
bonaﬁde AP-1 binding site multimer (Fig. 5B) and the wild-type BRCREO multimer (Fig. 5C). Importantly, these activa-
tions were speciﬁc, as c-Jun/Fra2 co-transfections did not stim-
ulate the activity of AP-1 multimer or BRCREO mutants. We
conclude that the putative CRE element within the BRCA1
promoter can act, at least in part, as a modiﬁed AP-1 response
element in ovarian cells.4. Discussion
Decreased BRCA1 expression in the absence of genetic
mutation occurs frequently in sporadic ovarian cancer and
the magnitude of this decrease correlates with poor outcome
[8,10,11,13]. This implies that signaling pathways governing
BRCA1 expression may be misregulated during ovarian
tumorigenesis [29]. Thus, we undertook the ﬁrst comparative
characterization of BRCA1 promoter regulation in OSE and
ovarian carcinoma cells. As is the case in breast carcinoma
cells, we found that two discrete elements, the RIBS and
CRE elements, each play important roles in the maximal acti-
vation of the promoter in ovarian cells.
Deletion of the RIBS element or mutation of the CRE ele-
ment alone completely abolished BRCA1 promoter activity
in ovarian cells. Thus, both elements are necessary, but alone
are not suﬃcient, to activate the promoter, which suggests that




Fig. 3. The CRE element has some CREB binding potential. (A) A schematic of the L6 promoter fragment illustrating the location and nature of the
WT and mutant BRCREO probe. (B) Nuclear extracts from IOSE-80pc and OVCAR-3 cells were used in bandshift assays with the wild-type
BRCREO probe in the presence or absence of an antibody against the CREB transcription factor. CREB-containing MCF10a cells were included,
and the supershifted DNA/protein complexes are indicated with arrows. (C and D) Competition bandshift assays were performed with nuclear
extracts from both IOSE-80pc (C) and OVCAR-3 (D) cells using labeled somatostatin-CRE probe alone or in the presence of increasing
concentrations of unlabeled competing oligonucleotides (wild-type BRCREO, mutant BRCREO, or self competing somatostatin-CRE probes).
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Fig. 4. The BRCA1 CRE element is not cAMP sensitive. (A) Western blot analysis of IOSE-80pc and OVCAR-3 cells either serum starved () or
stimulated with 20 lM Forskolin (+) and probed using an antibody directed against phosphorylated CREB at serine 133. The presence of phospho-
CREB (43 kDa) is indicated by the arrowhead, while a lower molecular weight non-speciﬁc band is indicated by the arrow. Actin is shown as a
loading control for protein concentration. (B and C) The transcriptional activities of a multimerized BRCREO element or a bonaﬁde CRE multimer
were compared to a minimal promoter in the presence of either DMSO (vehicle control, shaded bars) or 20 lM forskolin (black bars) in IOSE-80pc
(B) and OVCAR3 (C) cell lines. The data are expressed as the percentage activity relative to the DMSO-treated controls (mean ± S.D., n = 3; one
representative experiment of two).
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that both elements lie within a 56 bp minimal promoter [19],
which encompasses the separately identiﬁed ’positive regula-
tory region’ (PRR; Ref. [20]). We previously determined that
ETS-like GABP a/b complexes bind to the RIBS element with
functional consequence in breast cells [21]. Additionally, Croce
and colleagues found that single strand-binding replication
protein A (RPA) factors interact with a region that overlaps
the RIBS element [26]. Thus, the regulation of this region ap-
pears to be complex which certainly appears to be the case in
ovarian cells given that mutation of the putative ETS-binding
sites only partially reduced promoter activation.
The activity of the putative CRE element relies entirely upon
the conserved CpG within it as a single 2 base pair mutation
completely abolished its activity. Similar to the situation in
breast carcinoma cells [22,28], we demonstrated some CREB
binding to this element in nuclear extracts from ovarian cells,
and forskolin-mediated cAMP pathway activation did not
stimulate the CRE-element transcriptional activity. However,
we found that the AP-1 transcription factors c-Jun and Fra2
bind to and are able to positively regulate this element in ovar-
ian cells, which suggests this element may regulated in a tissue-
speciﬁc manner. This latter ﬁnding is likely signiﬁcant for two
reasons. Firstly, co-operativity between ETS and AP-1 factors
has been noted in other promoters [37,38]. Secondly, AP-1 sig-
naling is frequently dysregulated during tumor formation and
progression [39]. Given the fact that we saw slight diﬀerences
in how ETS site mutations aﬀected promoter activation in nor-
mal and tumor derived ovarian cells, it will now be important
to determine if such diﬀerences are magniﬁed when co-oper-
ativity between transcription factors is considered. Moreover,
such diﬀerences may be further inﬂuenced by changes to thetumor microenvironment, which may be particularly impor-
tant during ovarian tumorigenesis. For example, during the
onset of metastatic ovarian carcinoma progression, tumor
nodules are frequently shed from the surface of the ovary
where they ﬂoat freely in the abdominal cavity [30]. This rad-
ical change in the tumor microenvironment very likely alters
the status of a number of signaling pathways that may impinge
upon the activation state of the positive acting transcription
factors, like AP-1, and may consequently aﬀect the activity
of the BRCA1 promoter. For example, increased AKT phos-
phorylation is a well-documented marker in metastatic ovarian
cancer and is thought to confer important survival signals in
malignant ovarian eﬀusions [40,41]. Recently it has been
shown that an AKT-dependent signal mediates the nuclear
translocation of the Y-box-binding protein-1 (YB-1) [42],
which is frequently overexpressed in cancer and both its
expression and nuclear localization correlates with poor prog-
nosis and increased drug resistance in ovarian carcinoma
[43,44]. This AKT-dependent signaling pathway, which is
likely highly regulated by the tumor microenvironment, may
be important in regulating the BRCA1 promoter as YB-1
has been shown to repress AP-1 dependent gene transactiva-
tion [34]. We are currently undertaking experiments to directly
address this issue.
The BRCA1 promoter constitutes a large CpG island that is
hypermethylated in approximately 10–30% of spontaneous
ovarian epithelial carcinomas [14–16,45,46]. Importantly, this
hypermethylation correlates with decreased BRCA1 expres-
sion and poor clinical outcome [13]. One of the CpG targets
for methylation, based on in vitro hypermethylation studies
[28], is the precise site of the 2 basepair mutation within the
CRE element that completely abrogated BRCA1 promoter
AB
C
Fig. 5. The CRE element binds to, and is activated by, components of a modiﬁed AP-1 transcription factor complex. (A) Nuclear extracts from
IOSE-80pc and OVCAR-3 cells were used in bandshift assays with the BRCREO probe in the presence or absence (no Ab) of antibodies against
Fra2, c-Fos or c-Jun. Only the upper DNA/protein complexes are shown. The locations of supershifted complexes are indicated by arrows. (B and C)
IOSE-80pc and OVCAR-3 cells were co-transfected with multimerized wild-type or mutant AP-1 responsive reporters (B) or BRCREO (C) reporters
with either an empty vector or expression constructs for c-Jun alone, Fra2 alone, or c-Jun and Fra2 together. Reporter activity was then determined.
The data are expressed as the percentage activity relative to the wild-type reporter transfected with the vector control (mean ± S.D., n = 3; one
representative experiment of two).
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directly facilitate a decrease in BRCA1 expression that is rele-
vant to sporadic tumor progression in the ovary. It is not yet
clear, however, whether promoter methylation itself is the crit-
ical initiating event or if a promoter becomes more susceptible
to methylation after an initial transcriptional inactivation [47].
Regardless, the initial characterization we have carried out
here indicates that ovarian-speciﬁc transcriptional inactivationof BRCA1 is possible. This may be important given that the
suppression of BRCA1 expression in sporadic tumors can oc-
cur in the absence of promoter hypermethylation with some
frequency [12,48].Acknowledgments:We thank Sherri Kemp for excellent technical assis-
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